Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
Journal of Ovarian Research volume 16, Article number: 38 (2023)
Correction: J Ovarian Res 15, 130 (2022)
Following publication of the original article , the authors identified an error in Figs. 1, 5 and Additional file. The correct figures are shown below and updated Additional file 2 is also provided in this article. Also, the Ethics approval and consent to participate section was modified, below is the correct statement. The original article has been corrected.
Ethics approval and consent to participate
The use of stored human tissues in this study was approved by the Institutional Review Board of the Ohio State University Wexner Medical Center under Study Number: 2004C0124 and the Ohio State University’s OHRP Federal wide Assurance #00006378. No human subjects were directly consented for this study as the tissues were obtained from a biorepository. All procedures used in this study were authorized and conducted according to the guidelines of the Ohio State University Research Institute Ethics Committee. All animal experiments were following the Animal Experimentation Ethics of the Ohio State University Animal Experimentation Research Lab, and the ethics approval number for animal experimentation was 2012A00000008-R3.
Saini U, Smith BQ, Dorayappan KDP, et al. Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. J Ovarian Res. 2022;15:130. https://doi.org/10.1186/s13048-022-01054-5.
About this article
Cite this article
Saini, U., Smith, B.Q., Dorayappan, K.D.P. et al. Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. J Ovarian Res 16, 38 (2023). https://doi.org/10.1186/s13048-023-01111-7